Advertisement

Editor Profile

Mark V. Dahl, MD

Associate Editor

About the NEJM Journal Watch Dermatology Board

Mark V. Dahl, MD, is currently Professor of Dermatology, College of Medicine, Mayo Clinic, and Senior Consultant in the Department of Dermatology at Mayo Clinic in Scottsdale/Phoenix, Arizona. He has served as President of the American Academy of Dermatology and as Vice President of the Society for Investigative Dermatology. He is the founder of Camp Discovery, a camping program for children with severe skin diseases. Dr. Dahl is a recipient of the Gold Medal, the American Academy of Dermatology's highest honor, and was named a Master Dermatologist by the organization in 2006. His research has focused on immunology, infections, and inflammatory diseases of the skin, including studies related to immunodeficiency, chemotaxis, granuloma annulare, immunofluorescence, bullous diseases, psoriasis, cutaneous irritation, allergy, rosacea, the epidermal acetylcholine network, and cutaneous fungal infections. Dr. Dahl joined the NEJM Journal Watch Dermatology board in 2007.

Disclosures

Consultant / Advisory board

Genentech; Makucell, Inc.; Mayo Clinic

Speaker's bureau

Los Angeles Dermatological Society; University of Southern California

Equity

Elorac, Inc.; Johnson & Johnson; Pfizer

Editorial boards

UpToDate

Summaries by Mark Dahl

  • April 15, 2014

    BRAF-V600E and Langerhans Cell Histiocytosis

    1. Mark V. Dahl, MD

    LCH limited to skin and LCH affecting internal organs appear to originate from separate mutations with different degrees of risk for death.

  • April 4, 2014

    Ivermectin Mite Work
    Free

    1. Mark V. Dahl, MD

    Topical ivermectin 1% cream was effective for clearing papulopustular rosacea, and its antiparasitic action may be why.

  • March 21, 2014

    Mometasone Moment

    1. Mark V. Dahl, MD

    As a first-line treatment for vulvar lichen sclerosus, mometasone furoate appears to be as safe and effective as clobetasol propionate.

  • February 20, 2014

    Getting the Red Out, Office Style
    Free

    1. Mark V. Dahl, MD

    Brimonidine tartrate gel was well-tolerated and beneficial for aspects of moderate-to-severe erythematotelangiectatic rosacea.

  • February 14, 2014

    NF-κ Bleach

    1. Mark V. Dahl, MD

    Very dilute solutions of hypochlorite decreased the severity of dermatitis in mice.

  • February 14, 2014

    Sitter's Sign

    1. Mark V. Dahl, MD

    Hyperkeratotic lichenified skin lesion of the gluteal region is a cumbersome name that describes the condition very well.

Pages